Latest News and Press Releases

BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics (Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today...

Shares of Elicio to commence trading on Nasdaq under the ticker symbol “ELTX” on June 2, 2023First in human Phase 1 data on lead candidate ELI-002 to be presented at 2023 American Society of Clinical...

BOSTON, May 01, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases,...

The 7-peptide formulation of ELI-002 is designed to stimulate an immune response against seven KRAS mutations that drive 25% of all solid tumors, potentially defeating resistance mechanisms Study...

AMP-protein-based vaccines administered intranasally to mice and nonhuman primates (NHPs) were transported across the epithelial lining to the nasal-associated lymphoid tissue (NALT) and persisted...

Funds will advance research into ELI-007 as a mutant BRAF-peptide vaccine and ELI-008 as a p53 hotspot mutation-peptide vaccine, with the aim of developing multivalent cancer vaccines targeting...

Data published in bioRxiv shows ELI-005 administration safely promotes robust cellular and humoral immunity through potent and targeted engagement of the lymph nodes in mice and non-human primates...

Data showed that vaccination with AMP-CpG combined with EBV gp350 and EBVpoly proteins delivered directly to the lymph nodes rapidly induced potent gp350-specific antibodies (IgG), EBV neutralizing...

The presented data show ELI-005 elicits strong and long-lasting cellular and humoral immune responses that were maintained at significantly higher levels than comparator vaccines over 32 weeks in...

AMPLIFY-201 is a Phase 1 clinical study of ELI-002, a lymph node-targeted therapeutic cancer vaccine, in patients with mKRAS-driven cancers; the first patient was dosed at MD AndersonThe novel study...